Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis

Iris Navarro-Millán^{1

2}, Parag Goyal^{1

3}, Monika M Safford¹

Affiliations

¹ Department of Medicine, Division of General Internal Medicine, Weill Cornell Medicine, NY, USA.
² Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, NY, USA.
³ Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

Editorial

Iris Navarro-Millán et al. Rheumatology (Oxford). 2019.

. 2019 Jun 1;58(6):933-934.

doi: 10.1093/rheumatology/key302.

Iris Navarro-Millán^{1

2}, Parag Goyal^{1

3}, Monika M Safford¹

¹ Department of Medicine, Division of General Internal Medicine, Weill Cornell Medicine, NY, USA.
² Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, NY, USA.
³ Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

No abstract available

Comment in

Comment on: Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis.
Garton M, McInnes IB, Sattar N. Garton M, et al. Rheumatology (Oxford). 2020 Feb 1;59(2):453-454. doi: 10.1093/rheumatology/kez613. Rheumatology (Oxford). 2020. PMID: 31873738 No abstract available.
Comment on: Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis: reply.
Navarro-Millán I, Goyal P, Safford MM. Navarro-Millán I, et al. Rheumatology (Oxford). 2020 Feb 1;59(2):454-455. doi: 10.1093/rheumatology/kez489. Rheumatology (Oxford). 2020. PMID: 31873739 Free PMC article. No abstract available.

1. Barnabe C, Martin BJ, Ghali WA.. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63:522–9. - PubMed
1. Navarro-Millán I, Charles-Schoeman C, Yang S. et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum 2013;65:1430–8. - PMC - PubMed
1. Myasoedova E, Crowson CS, Kremers HM. et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011;70:482–7. - PMC - PubMed
1. Agca R, Heslinga SC, Rollefstad S. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76:17–28. - PubMed
1. An J, Alemao E, Reynolds K. et al. Cardiovascular outcomes associated with lowering low-density lipoprotein cholesterol in rheumatoid arthritis and matched nonrheumatoid arthritis. J Rheumatol 2016;43:1989–96. - PubMed